Please select the option that best describes you:
Topics:
Internal Medicine • Rheumatology • Vasculitis • ANCA Vasculitis • Pulmonology • Nephrology • ACR 2024 • Continue the Conversation
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?
This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeeting. This question was inspired by the session "Controversies in the Treatment of ANCA-associated Vasculitis" by Dr. Carol Langford and Dr. Philip Seo.
Answer from: at Academic Institution
This is an important question. Currently there are several groups of patients that benefit from reduced dose glucocorticoids:
- The largest group are patients who are receiving avacopan for remission induction. The ADVOCATE trial demonstrated that avacopan can markedly reduce the dose of glucocorti...
Sign in or Register to read more